A Phase I Study of JS108 in Patients With Advanced Solid Tumors
NCT ID: NCT04601285
Last Updated: 2023-07-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
25 participants
INTERVENTIONAL
2020-10-28
2023-06-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of HS-20105 for Injection in Patients With Advanced Solid Tumors.
NCT06144723
First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors
NCT06877650
Phase I Study of HS-20108 in Participants With Advanced Solid Tumors
NCT06936735
A Study of HS-20122 in Patients With Advanced Solid Tumors
NCT06927570
A Study Explore WJ01075 Tablets in Patients With Advanced Solid Tumors
NCT05470933
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose Escalation
JS108 (recombinant humanized anti-Trop2 mAb-Tub196 conjugate for injection)
Dose escalation period: JS108 is administered intravenously every three weeks (Q3W) at the dose corresponding to the enrolled dose cohort.
Dose expansion period: JS108 is administered intravenously Q3W at the corresponding dose.
Clinical expansion period: JS108 is administered intravenously Q3W at the recommended dose.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
JS108 (recombinant humanized anti-Trop2 mAb-Tub196 conjugate for injection)
Dose escalation period: JS108 is administered intravenously every three weeks (Q3W) at the dose corresponding to the enrolled dose cohort.
Dose expansion period: JS108 is administered intravenously Q3W at the corresponding dose.
Clinical expansion period: JS108 is administered intravenously Q3W at the recommended dose.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
10. Serum pregnancy test confirmed as negative for women of childbearing potential within 7
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Junshi Bioscience Co., Ltd.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JS108-001-I
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.